Pharmacogenetics of etanercept in rheumatoid arthritis

التفاصيل البيبلوغرافية
العنوان: Pharmacogenetics of etanercept in rheumatoid arthritis
المؤلفون: S. Louis Bridges, Maria I. Danila, Laura B. Hughes
المصدر: Pharmacogenomics. 9:1011-1015
بيانات النشر: Future Medicine Ltd, 2008.
سنة النشر: 2008
مصطلحات موضوعية: musculoskeletal diseases, Arthritis, Article, Receptors, Tumor Necrosis Factor, Etanercept, Arthritis, Rheumatoid, Genetics, medicine, Animals, Humans, skin and connective tissue diseases, Receptor, Pharmacology, business.industry, medicine.disease, Antirheumatic Agents, Pharmacogenetics, Immunoglobulin G, Rheumatoid arthritis, Immunology, Molecular Medicine, Tumor necrosis factor alpha, Personalized medicine, business, medicine.drug
الوصف: Etanercept is one of several TNF inhibitors approved for rheumatoid arthritis (RA) and a variety of other immune-mediated inflammatory conditions. Given the plethora of drugs approved for RA, and the wide variations in cost and treatment response, markers of efficacy would be very useful. Several candidate genes, including HLA-DRB1 alleles and those encoding TNF, TNF receptors and Fc receptors, have been examined for a role in the response to treatment with etanercept. In this review, we discuss pharmacogenetic studies of etanercept in RA and other diseases, and comment on the future of such analyses to advance the goal of personalized medicine in RA.
تدمد: 1744-8042
1462-2416
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3ec2a4a0ce7f24912d7794380518418Test
https://doi.org/10.2217/14622416.9.8.1011Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....e3ec2a4a0ce7f24912d7794380518418
قاعدة البيانات: OpenAIRE